Wsx1 expression in tumors induces immune tolerance via suppression of effector immune cells

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Dibra, Denada ^a   Cutrera, Jeffry ^a   Xia, Xueqing ^a   Li, Shulin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 27; ONCOPROTEIN; PROTEIN WSX1; UNCLASSIFIED DRUG; CYTOKINE; CYTOKINE RECEPTOR; IL27RA PROTEIN, MOUSE; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; LEWIS CARCINOMA; MELANOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TARGET CELL; TUMOR MICROENVIRONMENT; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COCULTURE; CONFOCAL MICROSCOPY; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE MUTANT; NATURAL KILLER CELL; PHYSIOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; IMMUNE SYSTEM; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-17; KILLER CELLS, NATURAL; MELANOMA; MICE; MICE, INBRED C57BL; MICE, SCID; MICROSCOPY, CONFOCAL; RECEPTORS, CYTOKINE; T-LYMPHOCYTES;

EID: 79955777815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019072     Document Type: Article

References (43)

1. Mapara MY, Sykes M, (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22: 1136-1151.
2. Mueller DL, (2010) Mechanisms maintaining peripheral tolerance. Nat Immunol 11: 21-27.
3. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
4. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034.
5. Nishimura H, Nose M, Hiai H, Minato N, Honjo T, (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11: 141-151.
6. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, et al. (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203: 883-895.
7. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH, (2002) Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168: 3771-3776.
8. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274.
9. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, et al. (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
10. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, et al. (2000) Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407: 916-920.
11. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, et al. (2004) WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 172: 2225-2231.
12. Dibra D, Cutrera JJ, Xia X, Birkenbach MP, Li S, (2009) Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res 69: 5505-5513.
13. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, et al. (2008) Antiproliferative activity of IL-27 on melanoma. J Immunol 180: 6527-6535.
14. Sprecher CA, Grant FJ, Baumgartner JW, Presnell SR, Schrader SK, et al. (1998) Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun 246: 82-90.
15. Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, et al. (2004) An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol 173: 3871-3877.
16. Tanner JW, Chen W, Young RL, Longmore GD, Shaw AS, (1995) The conserved box 1 motif of cytokine receptors is required for association with JAK kinases. J Biol Chem 270: 6523-6530.
17. Pradhan A, Lambert QT, Reuther GW, (2007) Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci U S A 104: 18502-18507.
18. Schoenherr C, Weiskirchen R, Haan S, (2010) Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription 1-dependent responses. Cell Commun Signal 8: 19.
19. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, et al. (2009) IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 183: 6217-6226.
20. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, et al. (2005) Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 115: 437-442.
21. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, et al. (2004) Potent antitumor activity of interleukin-27. Cancer Res 64: 1152-1156.
22. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, et al. (2004) IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 173: 7170-7182.
23. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, et al. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 66: 6395-6404.
24. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, et al. (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17: 19-29.
25. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, et al. (2007) Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447: 482-486.
26. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, et al. (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180: 7249-7258.
27. Condeelis J, Pollard JW, (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266.
28. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
29. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, et al. (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13: 828-835.
30. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, et al. (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med 2: 1361-1366.
31. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, et al. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366.
32. Sugiyama N, Nakashima H, Yoshimura T, Sadanaga A, Shimizu S, et al. (2008) Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor alpha (WSX-1). Ann Rheum Dis 67: 1461-1467.
33. Hu X, Ivashkiv LB, (2009) Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31: 539-550.
34. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261-268.
35. Thompson CB, Allison JP, (1997) The emerging role of CTLA-4 as an immune attenuator. Immunity 7: 445-450.
36. Hamano S, Himeno K, Miyazaki Y, Ishii K, Yamanaka A, et al. (2003) WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19: 657-667.
37. Siebler J, Wirtz S, Frenzel C, Schuchmann M, Lohse AW, et al. (2008) Cutting edge: a key pathogenic role of IL-27 in T cell- mediated hepatitis. J Immunol 180: 30-33.
38. Yamanaka A, Hamano S, Miyazaki Y, Ishii K, Takeda A, et al. (2004) Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J Immunol 172: 3590-3596.
39. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, et al. (2008) Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 67: 1474-1479.
40. Cao Y, Doodes PD, Glant TT, Finnegan A, (2008) IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol 180: 922-930.
41. Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, et al. (2009) Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 182: 4328-4338.
42. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, et al. (2006) Antiangiogenic and antitumor activities of IL-27. J Immunol 176: 7317-7324.
43. Sauer KA, Maxeiner JH, Karwot R, Scholtes P, Lehr HA, et al. (2008) Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells. J Immunol 181: 6148-6157.